for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Biohaven Says Achieved Both Co-Primary Regulatory Endpoints In Two Pivotal Phase 3 Trials Of Rimegepant

March 26 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd:

* BIOHAVEN ANNOUNCES SUCCESSFUL ACHIEVEMENT OF BOTH CO-PRIMARY REGULATORY ENDPOINTS IN TWO PIVOTAL PHASE 3 TRIALS OF RIMEGEPANT AN ORAL CGRP RECEPTOR ANTAGONIST FOR THE ACUTE TREATMENT OF MIGRAINE

* RESULTS ARE STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL ACROSS MULTIPLE OUTCOME MEASURES

* EFFICACY AND SAFETY RESULTS WERE CONSISTENT ACROSS BOTH PHASE 3 TRIALS.

* ON SCHEDULE TO SUBMIT AN NDA FOR RIMEGEPANT IN 2019 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up